Nasdaq and QCP Set New Standard of Capital Efficiency by Connecting Canton Network to Nasdaq Calypso
NEW YORK, June 26, 2025 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today announced it has facilitated end-to-end margin and collateral workflows on the Canton Network, connecting the blockchain-based technology to Nasdaq Calypso. The use case was developed in partnership with QCP, Primrose Capital Management and Digital Asset, to demonstrate that the integration of on-chain capabilities alongside existing institutional workflows enhances collateral mobility across all asset classes for institutional market participants.
Nasdaq Calypso is the leading technology platform used by financial institutions to seamlessly manage risk, margin, and collateral needs in an integrated environment. Its technology is uniquely positioned to serve the evolving demands of both traditional finance and emerging digital markets. Through the partnership on this use case, Nasdaq Calypso will expand its capabilities to support automated 24/7 margin and collateral management across a full spectrum of assets, including crypto derivatives, fixed income, exchange-traded derivatives, and over-the-counter derivatives.
With this partnership, the companies are seeking to mature and scale the next generation of digital asset infrastructure. The use case represents a proof point that leveraging blockchain-based technology for collateral management allows financial institutions to meet the demands for real-time capital efficiency in an always-on financial ecosystem. It enables financial institutions to allocate capital more efficiently by mobilizing and redeploying previously locked up collateral across markets.
Melvin Deng, CEO of QCP, said: 'Partnering with a global technology leader like Nasdaq is a testament to our commitment to building the next generation of institutional-grade market infrastructure. This isn't just a technological milestone, it's a paradigm shift for capital efficiency. Automating collateral management on-chain allows us to offer our clients enhanced security, better pricing, and the ability to deploy capital 24/7 across both traditional and digital assets. QCP played a pivotal role in shaping the product design and market integration and will support Nasdaq on developing a new suite of OTC spot and derivatives products, setting a new standard for what's possible in institutional digital assets.'
Yuval Rooz, Co-Founder & CEO of Digital Asset, said: 'This milestone with Nasdaq, QCP, and Primrose shows how Canton can meaningfully enhance institutional workflows. By automating margin and collateral processes on chain, firms gain real-time efficiency and control while maintaining data confidentiality through configurable privacy settings. It's a major step toward harmonizing traditional and digital markets on a trusted, interoperable infrastructure.'
Linus Ong, Chief Investment Officer, Primrose Capital Management, said: 'Primrose operates at the intersection of quantitative trading and digital asset innovation. This integration empowers our fund to align our portfolio management and real-time risk management with institutional-grade on-chain infrastructure. It brings the discipline of quant finance to a 24/7 digital market.'
Enhancing trust in the infrastructure and networks that underpin the digital asset ecosystem will also be critical to the long-term development of the asset class.
Magnus Haglind, Head of Marketplace Technology, Nasdaq, said: 'Capital market infrastructure and the emerging digital asset ecosystem are on the cusp of a generational shift as they converge with faster settlement and 24- hour trading, driving a new operational paradigm for market participants. Financial institutions need to improve real time risk management and mobilize collateral to optimize capital and liquidity deployment. We are excited to work with our clients to deliver improved capital efficiency through this innovative solution.'
Through a comprehensive suite of digital asset products and services, Nasdaq is committed to supporting the evolution of the digital asset ecosystem by helping to drive resilience and integrity across the market.
Nasdaq plans to advance its existing digital asset capabilities across its suite of capital market solutions, helping to drive institutional adoption of digital assets. Around the world, Nasdaq's technology is used by 97% of global systematically important banks, half of the world's top 25 stock exchanges, 35 central banks and regulatory authorities, and 3,800+ clients across the financial services industry. As a scaled platform partner, Nasdaq draws on deep industry experience, technology expertise, and cloud managed service experience to help financial services companies solve their toughest operational challenges while advancing industrywide modernization.
About Nasdaq
Nasdaq (Nasdaq: NDAQ) is a leading global technology company serving corporate clients, investment managers, banks, brokers, and exchange operators as they navigate and interact with the global capital markets and the broader financial system. We aspire to deliver world-leading platforms that improve the liquidity, transparency, and integrity of the global economy. Our diverse offering of data, analytics, software, exchange capabilities, and client-centric services enables clients to optimize and execute their business vision with confidence. To learn more about the company, technology solutions, and career opportunities, visit us on LinkedIn, on X @Nasdaq, or at www.nasdaq.com.
Media Contacts:
Andrew Hughes; +44 (0)7443 100896; [email protected]
Camille Stafford; +1 (234) 934 9513; [email protected]
-NDAQG-
Cautionary Note Regarding Forward-Looking Statements:
Information set forth in this press release contains forward-looking statements that involve a number of risks and uncertainties. Nasdaq cautions readers that any forward-looking information is not a guarantee of future performance and that actual results could differ materially from those contained in the forward-looking information. Forward-looking statements can be identified by words such as 'will', 'can' and other words and terms of similar meaning. Such forward-looking statements include, but are not limited to, statements related to the benefits of Nasdaq's digital asset margin management technology. Forward-looking statements involve a number of risks, uncertainties or other factors beyond Nasdaq's control. These risks and uncertainties are detailed in Nasdaq's filings with the U.S. Securities and Exchange Commission, including its annual reports on Form 10-K and quarterly reports on Form 10-Q which are available on Nasdaq's investor relations website at http://ir.nasdaq.com and the SEC's website at www.sec.gov. Nasdaq undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
18 minutes ago
- Yahoo
Walgreens (NASDAQ:WBA) Exceeds Q2 Expectations
Pharmacy chain Walgreens Boots Alliance (NASDAQ:WBA) reported Q2 CY2025 results topping the market's revenue expectations , with sales up 7.2% year on year to $38.99 billion. Its non-GAAP profit of $0.38 per share was 11.3% above analysts' consensus estimates. Is now the time to buy Walgreens? Find out in our full research report. "On March 6, 2025, WBA entered into a definitive agreement to be acquired by entities affiliated with Sycamore Partners. The merger is currently expected to close in the third or fourth quarter of calendar year 2025, pending shareholder and regulatory approvals and other conditions to closing. Upon completion of the transaction, WBA common stock will no longer be listed on the Nasdaq Stock Market, and WBA will become a private company." Revenue: $38.99 billion vs analyst estimates of $36.59 billion (7.2% year-on-year growth, 6.5% beat) Adjusted EPS: $0.38 vs analyst estimates of $0.34 (11.3% beat) Operating Margin: 0.1%, in line with the same quarter last year Free Cash Flow Margin: 0.9%, similar to the same quarter last year Market Capitalization: $9.78 billion Primarily offering prescription medicine, health, and beauty products, Walgreens Boots Alliance (NASDAQ:WBA) is a pharmacy chain formed through the 2014 major merger of American company Walgreens and European company Alliance Boots. A company's long-term sales performance is one signal of its overall quality. Any business can put up a good quarter or two, but the best consistently grow over the long haul. With $154.6 billion in revenue over the past 12 months, Walgreens is a behemoth in the consumer retail sector and benefits from economies of scale, giving it an edge in distribution. This also enables it to gain more leverage on its fixed costs than smaller competitors and the flexibility to offer lower prices. However, its scale is a double-edged sword because it's harder to find incremental growth when you've penetrated most of the market. To expand meaningfully, Walgreens likely needs to tweak its prices or enter new markets. As you can see below, Walgreens grew its sales at a sluggish 3.8% compounded annual growth rate over the last six years (we compare to 2019 to normalize for COVID-19 impacts). This shows it failed to generate demand in any major way and is a rough starting point for our analysis. This quarter, Walgreens reported year-on-year revenue growth of 7.2%, and its $38.99 billion of revenue exceeded Wall Street's estimates by 6.5%. Looking ahead, sell-side analysts expect revenue to decline by 1.6% over the next 12 months, a deceleration versus the last six years. This projection is underwhelming and indicates its products will see some demand headwinds. Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. Same-store sales is a key performance indicator used to measure organic growth at brick-and-mortar shops for at least a year. Walgreens has been one of the most successful retailers over the last two years thanks to skyrocketing demand within its existing locations. On average, the company has posted exceptional year-on-year same-store sales growth of 6.7%. Note that Walgreens reports its same-store sales intermittently, so some data points are missing in the chart below. We were impressed by how significantly Walgreens blew past analysts' revenue expectations this quarter. We were also happy its EPS outperformed Wall Street's estimates. No guidance was provided due to the impending acquisition of the company. Zooming out, we think this was a solid quarter. The stock remained flat at $11.40 immediately after reporting. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
USA Today
20 minutes ago
- USA Today
Jaguar Health Board of Directors Authorizes Company to Include Cryptocurrency as a Treasury Reserve Asset
Strategic decision positions Jaguar to diversify treasury holdings with a long-term digital store of value Jaguar Health, Inc. ( NASDAQ:JAGX ) ('Jaguar' or 'the Company'), announced today that its Board of Directors has unanimously authorized the Company to include cryptocurrency as a treasury reserve asset. 'Cryptocurrencies continue to gain investor attention and acceptance as a major asset class. We believe selected cryptocurrencies could serve as a strong treasury reserve asset for the Company, diversifying our assets to include a digital store of value that we believe has significant upside potential and may also provide a safeguard against inflation,' said Lisa Conte, Jaguar's Founder and CEO. 'Jaguar has been approached by several banks and an investor with terms for cryptocurrency transactions. The Company is assessing the potential value to shareholders, and the potential benefits for our core development programs, of making selected cryptocurrencies a treasury reserve asset for the Company.' Jaguar's has three core development programs for crofelemer, the Company's novel plant-based prescription medicine: its orphan disease intestinal failure program; its ongoing efforts to make crofelemer available for treatment of cancer therapy-related diarrhea (CTD) in patients with metastatic breast cancer receiving selected targeted therapies; and its ongoing development program to expand access for Canalevia® (crofelemer delayed-release tablets) in dogs from the conditional approval in chemotherapy-induced diarrhea to a potential global approval for acute general diarrhea. Each of these core programs for crofelemer is the subject of business development goals of forging corporate partnerships to bring in non-dilutive funding for the Company. About the Jaguar Health Family of Companies Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo's crofelemer is FDA-approved under the brand name Mytesi® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications. For more information about: Jaguar Health, visit Napo Pharmaceuticals, visit Napo Therapeutics, visit Magdalena Biosciences, visit Canalevia-CA1, visit Visit the Make Cancer Less Shitty patient advocacy program on Bluesky, X, Facebook & Instagram Forward-Looking Statements Certain statements in this press release constitute 'forward-looking statements.' These include statements regarding making selected cryptocurrencies a treasury reserve asset for the Company, Jaguar's belief that selected cryptocurrencies could serve as a strong treasury reserve asset for the Company, Jaguar's belief that there may be significant upside potential in diversifying the Company's assets to include a digital store of value, Jaguar's belief that diversifying the Company's assets to include a digital store of value may provide a safeguard against inflation, the potential value to shareholders of making selected cryptocurrencies a treasury reserve asset for the Company, and the potential benefits for Jaguar's core development programs of making selected cryptocurrencies a treasury reserve asset for the some cases, you can identify forward-looking statements by terms such as 'may,' 'will,' 'should,' 'expect,' 'plan,' 'aim,' 'anticipate,' 'could,' 'intend,' 'target,' 'project,' 'contemplate,' 'believe,' 'estimate,' 'predict,' 'potential' or 'continue' or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. CONTACT: hello@ Jaguar-JAGX SOURCE: Jaguar Health, Inc. View the original press release on ACCESS Newswire
Yahoo
22 minutes ago
- Yahoo
Mastercard expands partnership with Fiserv to integrate FIUSD stablecoin
Mastercard has expanded its collaboration with Fiserv to incorporate the FIUSD token, a new programmable blockchain-based stablecoin, into its global payment network. The partnership aims to address the practical use cases and challenges associated with the adoption of stablecoins. It aims to facilitate the transition between fiat currencies and FIUSD for both consumers and businesses for on/off-ramping processes. Mastercard will also enable FIUSD as a settlement option for its global acquirers, allowing merchants to receive payments in FIUSD regardless of the payment method used. Mastercard Americas co-president Chiro Aikat stated: 'Leveraging the power of the Mastercard network, as well as our deep capabilities across digital assets, we are creating a robust ecosystem that bridges traditional financial services with digital assets. 'Underpinned by our commitment to providing seamless, secure and programmable transactions, we are excited to bring Fiserv's FIUSD to our customers, consumers and businesses around the world.' The collaboration will leverage the Mastercard Multi-Token Network (MTN), allowing Fiserv's Digital Asset Platform, which is powered by Finxact, to support programmable on-chain commerce for banks. Furthermore, it will issue stablecoin-linked cards, permitting the use of FIUSD for transactions at any Mastercard-accepting location around the world. Mastercard One Credential will also be available, providing consumers with the option to select their preferred payment method, including stablecoin balances, in addition to traditional debit and credit. Fiserv chief operating officer Takis Georgakopoulos said: 'FIUSD presents Fiserv customers with access to a new, more efficient, and interoperable digital asset service for their banking and payment flows. 'Our work with Mastercard is promoting greater reach and utility of stablecoins by helping our financial institutions and merchants enable greater payments choice to their customers." This expansion follows the Fiserv announcement to launch a new digital asset platform by the end of 2025. The platform will include the FIUSD stablecoin and is set to be integrated into Fiserv's existing banking and payment infrastructure. "Mastercard expands partnership with Fiserv to integrate FIUSD stablecoin " was originally created and published by Electronic Payments International, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
